39481-55-5

Usage

Uses

Used in Pharmaceutical Industry:
1-[10-(3-chloropropyl)-10H-phenothiazin-2-yl]ethan-1-one is used as an intermediate in the synthesis of Acetophenazine Dimaleate (A163930), an antipsychotic agent. Its chemical structure allows for the development of medications that can help in the treatment of psychiatric disorders by targeting specific receptors in the brain.
1-[10-(3-chloropropyl)-10H-phenothiazin-2-yl]ethan-1-one's role as an intermediate in the synthesis of antipsychotic agents highlights its importance in the pharmaceutical industry, where it contributes to the development of drugs that can alleviate symptoms associated with mental health conditions.

InChI:InChI=1/C17H16ClNOS/c1-12(20)13-7-8-17-15(11-13)19(10-4-9-18)14-5-2-3-6-16(14)21-17/h2-3,5-8,11H,4,9-10H2,1H3

Upstream product

• 6940-76-7 1-iodo-3-chloro-propane 
• 6631-94-3 2-acetylphenothiazine 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 98271-51-3 2-Acetyl-10-<3-piperidino-propyl>-phenothiazin 
• 61-00-7 acetopromazine 

Relevant academic research and scientific papers

An Inhibitor of the Interaction of Survivin with Smac in Mitochondria Promotes Apoptosis

Herein we report the first small molecule that disrupts the survivin-Smac interaction taking place in mitochondria. The inhibitor, PZ-6-QN, was identified by initially screening a phenothiazine library using a fluorescence anisotropy assay and then conducting a structure–activity relationship study. Mutagenesis and molecular docking studies suggest that PZ-6-QN binds to survivin similarly to the known Smac peptide, AVPI. The results of the effort also show that PZ-6-QN exhibits good anticancer activity against various cancer cells. Moreover, cell-based mechanistic studies provide evidence for the proposal that PZ-6-QN enters mitochondria to inhibit the survivin-Smac interaction and promotes release of Smac and cytochrome c from mitochondria into the cytosol, a process that induces apoptosis in cancer cells. Overall, the present study suggests that PZ-6-QN can serve as a novel chemical probe for study of processes associated with the mitochondrial survivin-Smac interaction and it will aid the discovery of novel anticancer agents.

Synthesis and pharmacological characterization of novel inverse agonists acting on the viral-encoded chemokine receptor US28

G-protein coupled receptors encoded by viruses represent an unexplored class of potential drug targets. In this study, we describe the synthesis and pharmacological characterization of the first class of inverse agonists acting on the HCMV-encoded receptor US28. It is shown that replacement of the 4-hydroxy group of lead compound 1 with a methylamine group results in a significant 6-fold increase in affinity. Interestingly, increasing the rigidity of the spacer by the introduction of a double bond also leads to a significant increase in binding affinity compared to 1. These novel inverse agonists serve as valuable tools to elucidate the role of constitutive signaling in the pathogenesis of viral infection and may have therapeutic potential as leads for new antiviral drugs.

Identification of a non peptidic RANTES antagonist

A series of phenothiazines demonstrating inhibition of RANTES binding to THP-1 cell membranes has been identified. The lead compound RP23618 (IC50 = 3 μM) was found to inhibit specific binding of 125I-RANTES, but not 125I-MCP-1 to THP-1 cell membranes and furthermore to antagonise RANTES, but not MCP-1-induced chemotaxis of THP-1 cells.